Faron Pharmaceuticals Oy (LON:FARN) Reaches New 12-Month Low – Here’s Why

Faron Pharmaceuticals Oy (LON:FARN) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 38 and last traded at GBX 38.70, with a volume of 95836 shares trading hands. The stock had previously closed at GBX 41.

Faron Pharmaceuticals Oy Price Performance

The company has a current ratio of 0.84, a quick ratio of 1.09 and a debt-to-equity ratio of -133.35. The firm has a market cap of £48.72 million, a PE ratio of -1.75 and a beta of 1.18. The business has a fifty day moving average of GBX 47.45 and a 200-day moving average of GBX 128.66.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.